Estradiol/nomegestrol sequential

Drug Profile

Estradiol/nomegestrol sequential

Alternative Names: E2/Nomac sequential; EMM 210066; Naemis; Nomac/E2 sequential; TX 45066

Latest Information Update: 06 Jan 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Theramex SAM
  • Class Estradiol congeners; Estrenes; Hormonal contraceptives; Hormonal replacements; Pregnadienes; Progesterone congeners; Small molecules
  • Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Menopausal syndrome

Most Recent Events

  • 06 Jan 2011 Theramex SAM has been acquired by Teva Pharmaceutical Industries
  • 31 Dec 2003 Launched for Menopausal syndrome in Europe (PO) - First global launch
  • 15 Nov 2001 This product is available for licensing in the US and Japan (http://www.theramex.mc)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top